スポンサーリンク
National Cancer Center Hospital East Oncology/hematology | 論文
- Genetic Variations and Haplotypes of ABCC2 Encoding MRP2 in a Japanese Population
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Twelve Novel Single Nucleotide Polymorphisms in the CES2 Gene Encoding Human Carboxylesterase 2 (hCE-2)
- Genetic Variations and Frequencies of Major Haplotypes in SLCO1B1 Encoding the Transporter OATP1B1 in Japanese Subjects : SLCO1B1^*17 is More Prevalent Than ^*15
- 日本人におけるヒトSLC29A1の新規遺伝子多型の同定
- Genetic Variation and Haplotype Structure of the ABC Transporter Gene ABCG2 in a Japanese Population
- Genetic Variations and Haplotypes of UGT1A4 in a Japanese Population
- Genetic Polymorphisms of UGT1A6 in a Japanese Population
- Genetic Variations of the AHR Gene Encoding Aryl Hydrocarbon Receptor in a Japanese Population
- Three Novel Single Nucleotide Polymorphisms in UGT1A9
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Novel Genetic Polymorphisms in the NR3C1 (Glucocorticoid receptor) Gene in a Japanese Population
- Twenty-six Novel Single Nucleotide Polymorphisms and their Frequencies of the NR113 (CAR) Gene in a Japanese Population
- Eight Novel Single Nucleotide Polymorphisms in ABCG2/BCRP in Japanese Cancer Patients Administered Irinotacan
- Three novel single nucleotide polymorphisms in UGT1A10
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases
- Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
- Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
- Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
- Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice